GB2539472A - Use of cannabinoids in the treatment of epilepsy - Google Patents

Use of cannabinoids in the treatment of epilepsy Download PDF

Info

Publication number
GB2539472A
GB2539472A GB1510664.4A GB201510664A GB2539472A GB 2539472 A GB2539472 A GB 2539472A GB 201510664 A GB201510664 A GB 201510664A GB 2539472 A GB2539472 A GB 2539472A
Authority
GB
United Kingdom
Prior art keywords
cbd
seizures
treatment
cannabidiol
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1510664.4A
Other languages
English (en)
Other versions
GB201510664D0 (en
Inventor
Guy Geoffrey
Wright Stephen
Mead Alice
Cheetham Emma
Devinsky Orrin
Schiller Dominic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Research UK Ltd
Original Assignee
GW Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53784899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2539472(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GW Research Ltd filed Critical GW Research Ltd
Priority to GB1510664.4A priority Critical patent/GB2539472A/en
Publication of GB201510664D0 publication Critical patent/GB201510664D0/en
Priority to CA2989779A priority patent/CA2989779C/en
Priority to MX2021003331A priority patent/MX2021003331A/es
Priority to MX2017016212A priority patent/MX381089B/es
Priority to US15/183,947 priority patent/US10709671B2/en
Priority to NZ738403A priority patent/NZ738403B2/en
Priority to JP2017565998A priority patent/JP6983076B2/ja
Priority to AU2016278088A priority patent/AU2016278088B2/en
Priority to EP21203376.5A priority patent/EP3984531A1/en
Priority to HK18112785.4A priority patent/HK1253580A1/zh
Priority to PCT/GB2016/051792 priority patent/WO2016203239A1/en
Priority to EP16731281.8A priority patent/EP3310390A1/en
Publication of GB2539472A publication Critical patent/GB2539472A/en
Priority to MX2022015027A priority patent/MX2022015027A/es
Priority to US16/893,018 priority patent/US11357741B2/en
Priority to AU2021269374A priority patent/AU2021269374B2/en
Priority to JP2021189417A priority patent/JP2022033807A/ja
Priority to US17/744,224 priority patent/US12064399B2/en
Priority to US18/762,588 priority patent/US20240350428A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0203—Solvent extraction of solids with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0288—Applications, solvents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0013—Crystallisation cooling by heat exchange by indirect heat exchange

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GB1510664.4A 2015-06-17 2015-06-17 Use of cannabinoids in the treatment of epilepsy Withdrawn GB2539472A (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GB1510664.4A GB2539472A (en) 2015-06-17 2015-06-17 Use of cannabinoids in the treatment of epilepsy
EP16731281.8A EP3310390A1 (en) 2015-06-17 2016-06-16 Use of cannabinoids in the treatment of epilepsy
MX2021003331A MX2021003331A (es) 2015-06-17 2016-06-16 Uso de cannabinoides en el tratamiento de epilepsia.
AU2016278088A AU2016278088B2 (en) 2015-06-17 2016-06-16 Use of cannabinoids in the treatment of epilepsy
PCT/GB2016/051792 WO2016203239A1 (en) 2015-06-17 2016-06-16 Use of cannabinoids in the treatment of epilepsy
MX2017016212A MX381089B (es) 2015-06-17 2016-06-16 Uso de cannabinoides en el tratamiento de epilepsia.
US15/183,947 US10709671B2 (en) 2015-06-17 2016-06-16 Use of cannabinoids in the treatment of epilepsy
NZ738403A NZ738403B2 (en) 2016-06-16 Use of cannabinoids in the treatment of epilepsy
JP2017565998A JP6983076B2 (ja) 2015-06-17 2016-06-16 てんかんの治療におけるカンナビノイドの使用
CA2989779A CA2989779C (en) 2015-06-17 2016-06-16 Use of cannabinoids in the treatment of epilepsy
EP21203376.5A EP3984531A1 (en) 2015-06-17 2016-06-16 Use of cannabidiol for the treatment of focal seizures in dravet syndrome
HK18112785.4A HK1253580A1 (zh) 2015-06-17 2016-06-16 大麻二酚在治疗癫痫中的用途
MX2022015027A MX2022015027A (es) 2015-06-17 2017-12-13 Uso de cannabinoides en el tratamiento de epilepsia.
US16/893,018 US11357741B2 (en) 2015-06-17 2020-06-04 Use of cannabinoids in the treatment of epilepsy
AU2021269374A AU2021269374B2 (en) 2015-06-17 2021-11-17 Use of cannabinoids in the treatment of epilepsy
JP2021189417A JP2022033807A (ja) 2015-06-17 2021-11-22 てんかんの治療におけるカンナビノイドの使用
US17/744,224 US12064399B2 (en) 2015-06-17 2022-05-13 Use of cannabinoids in the treatment of epilepsy
US18/762,588 US20240350428A1 (en) 2015-06-17 2024-07-02 Use of cannabinoids in the treatment of epilepsy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1510664.4A GB2539472A (en) 2015-06-17 2015-06-17 Use of cannabinoids in the treatment of epilepsy

Publications (2)

Publication Number Publication Date
GB201510664D0 GB201510664D0 (en) 2015-07-29
GB2539472A true GB2539472A (en) 2016-12-21

Family

ID=53784899

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1510664.4A Withdrawn GB2539472A (en) 2015-06-17 2015-06-17 Use of cannabinoids in the treatment of epilepsy

Country Status (8)

Country Link
US (4) US10709671B2 (enExample)
EP (2) EP3310390A1 (enExample)
JP (2) JP6983076B2 (enExample)
AU (2) AU2016278088B2 (enExample)
GB (1) GB2539472A (enExample)
HK (1) HK1253580A1 (enExample)
MX (3) MX2021003331A (enExample)
WO (1) WO2016203239A1 (enExample)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2551987A (en) * 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
WO2019064031A1 (en) 2017-09-29 2019-04-04 GW Research Limited USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINES IN THE TREATMENT OF EPILEPSY
GB2568471A (en) * 2017-11-15 2019-05-22 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2019106386A1 (en) * 2017-12-01 2019-06-06 GW Research Limited Use of cannabinoids in the treatment of epilepsy
GB2572737A (en) * 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2579179A (en) * 2018-11-21 2020-06-17 Gw Res Ltd Cannabidiol-type cannabinoid compound
EP3684411A1 (en) * 2017-09-19 2020-07-29 Zynerba Pharmaceuticals, Inc. Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
GB2588460A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
GB2590187A (en) * 2019-11-21 2021-06-23 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB2592117A (en) * 2019-12-19 2021-08-18 Gw Res Ltd Oral cannabinoid formulations
US11154516B2 (en) 2014-06-17 2021-10-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11154517B2 (en) 2014-10-14 2021-10-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11160795B2 (en) 2020-02-27 2021-11-02 GW Research Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11229612B2 (en) 2016-07-01 2022-01-25 GW Research Limited Parenteral formulations
GB2597287A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597321A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597286A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes
GB2597303A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
GB2597291A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597301A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with herpes simplex virus
GB2597305A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597293A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597302A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage
WO2022017917A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Cannabidiol for use in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017949A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with chrna4 mutation
WO2022017915A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Cannabidiol for use in the treatment of seizures associated with brain damage
WO2022017940A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Cannabidiol for use in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022017931A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with ohtahara syndrome or ohtahara syndrome secondary to aimp1 mutation
GB2599203A (en) * 2020-07-20 2022-03-30 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
US11357741B2 (en) 2015-06-17 2022-06-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
GB2601755A (en) * 2020-12-08 2022-06-15 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes
US11400055B2 (en) 2014-10-14 2022-08-02 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US11426362B2 (en) 2017-02-17 2022-08-30 GW Research Limited Oral cannabinoid formulations
EP4048241A1 (en) * 2019-10-25 2022-08-31 GW Research Limited Use of cannabidiol preparations in the treatment of absence epilepsy
US11793770B2 (en) 2014-06-27 2023-10-24 GW Research Limited 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
US11806319B2 (en) 2018-01-03 2023-11-07 GW Research Limited Pharmaceutical composition comprising a cannabinoid
US12263139B2 (en) 2017-06-23 2025-04-01 Jazz Pharmaceuticals Research Uk Limited Use of cannabidiol in the treatment of tuberous sclerosis complex
US12569505B2 (en) 2022-08-12 2026-03-10 Jazz Pharmaceuticals Research Uk Limited Oral solid dosage forms comprising cannabinoids
US12661365B2 (en) 2020-06-18 2026-06-23 Jazz Pharmaceuticals Research Uk Limited Use of cannabidiol in the treatment of epilepsy

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
DK3261640T3 (da) 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser
CN107771265A (zh) 2015-05-04 2018-03-06 江森自控科技公司 使用透明屏幕技术的可安装触摸恒温器
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
EP3364993B1 (en) 2015-10-22 2022-11-09 Cavion, Inc. Methods for treating angelman syndrome
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
EP3471746A4 (en) 2016-06-15 2020-02-26 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR TREATING CRAMPING SEASONS
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
EP3615521A4 (en) 2017-04-26 2021-02-17 Cavion, Inc. METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS
CA3061712A1 (en) * 2017-04-26 2018-11-01 Cavion, Inc. Methods for treating dravet syndrome
WO2019082171A1 (en) * 2017-10-27 2019-05-02 Alvit Pharma ORAL CANNABINOID COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2020039262A1 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceuticals solution for oral dosage
JP7480131B2 (ja) 2018-10-03 2024-05-09 カビオン・インコーポレイテッド （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
GB2580653A (en) * 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2586026A (en) * 2019-07-29 2021-02-03 Gw Res Ltd Use of cannabidol in the treatment of Dravet syndrome
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB2597283A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597297A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597312A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597299A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597313A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597308A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
GB2606334A (en) * 2021-02-12 2022-11-09 Gw Res Ltd Use of cannabidivarin in the treatment of seizures associated with canine epilepsy
WO2023200906A1 (en) 2022-04-12 2023-10-19 Shackelford Pharma Inc. Treatment of seizure disorders
WO2024058812A1 (en) 2022-09-16 2024-03-21 Pyros Pharmaceuticals, Inc. Vigabatrin liquid pharmaceutical composition
US11931369B1 (en) 2023-07-24 2024-03-19 Poviva Corp Compositions and methods for treating epilepsy
US12023346B1 (en) 2023-07-24 2024-07-02 Poviva Corp Compositions and methods for treating epilepsy
US11944635B1 (en) 2023-07-24 2024-04-02 Poviva Corp Compositions and methods for treating epilepsy
US11986485B1 (en) 2023-07-24 2024-05-21 Poviva Corp Compositions and methods for treating epilepsy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2485291A (en) * 2009-07-03 2012-05-09 Gw Pharma Ltd Cannabidiol (CBD) for use in the treatment of generalised and/or partial seizures
WO2015193667A1 (en) * 2014-06-17 2015-12-23 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2304669A (en) 1940-08-16 1942-12-08 Adams Roger Isolation of cannabidiol
JPS5430146A (en) 1977-08-05 1979-03-06 Microbial Chem Res Found Novel anthracycline derivatives and their preparation
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
DE10051427C1 (de) 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
DK1361864T3 (en) 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
GB2377633A (en) 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
GB2380129B (en) 2001-02-14 2004-08-11 Gw Pharma Ltd Pharmaceutical formulations
GB2381194A (en) 2001-09-07 2003-04-30 Gw Pharmaceuticals Ltd Pharmaceutical formulations
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
GB2377218A (en) 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
GB2381450B (en) 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
EP1542657B8 (en) 2002-08-14 2012-03-14 GW Pharma Limited Cannabinoid liquid formulations for mucosal amdinistration
MXPA05001621A (es) 2002-08-14 2005-08-19 Gw Pharma Ltd Extraccion de cannabinoides farmaceuticamente activos de materiales vegetales.
US10538373B2 (en) 2002-08-14 2020-01-21 Gw Pharma Limited Pharmaceutical formulation
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
GB2393182B (en) 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
US20040110828A1 (en) 2002-11-27 2004-06-10 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
WO2005065069A2 (en) 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
IL160420A0 (en) 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
WO2006017892A1 (en) 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en) 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
WO2007032962A2 (en) 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
EP2578561A1 (en) 2005-09-29 2013-04-10 Albany Molecular Research, Inc. Processes for the production of cannabidiol derivatives and intermediates thereof
GB2432312A (en) 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
PT1903866E (pt) * 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
US20070173770A1 (en) 2006-01-23 2007-07-26 The Medical House Plc Injection device
WO2007142957A2 (en) 2006-05-30 2007-12-13 Air Systems Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
US20080112895A1 (en) 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
US20110150825A1 (en) 2006-11-14 2011-06-23 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions
US20080188461A1 (en) 2007-02-01 2008-08-07 Regents Of The University Of Michigan Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
CN101040855A (zh) 2007-04-12 2007-09-26 杨喜鸿 含有利莫那班和泊洛沙姆的组合物、固体分散体及其制备和药物应用
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
WO2008144475A1 (en) 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
EP2023121A1 (en) 2007-07-06 2009-02-11 Bp Oil International Limited Optical cell
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
DK2176208T3 (en) 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
WO2009020666A1 (en) 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
US9023322B2 (en) 2008-03-26 2015-05-05 Stichting Sanammad Chewing gum compositions comprising cannabinoids
GB2475183B (en) 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
US20110257256A1 (en) 2008-07-31 2011-10-20 Bionoria Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
US8809261B2 (en) * 2008-10-31 2014-08-19 Elsohly Laboratories, Incorporated Compositions containing delta-9-THC-amino acid esters and process of preparation
WO2010127033A1 (en) 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
EP2424568A1 (en) 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
ES2409055T3 (es) 2009-06-29 2013-06-24 Bender Analytical Holding B.V. Sistema de suministro de fármacos que comprende polioxazolina y un agente bioactivo
US8735374B2 (en) 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
US20110033529A1 (en) 2009-08-06 2011-02-10 Durga Prasad Samantaray Oral pharmaceutical paricalcitol formulations
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
GB2487183B (en) 2011-01-04 2018-10-03 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
AU2011264941B2 (en) 2010-06-07 2014-10-16 Suda Ltd Oral spray formulations and methods for administration of sildenafil
EP3459533A1 (en) 2010-08-04 2019-03-27 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
WO2012033478A1 (en) 2010-09-07 2012-03-15 Murty Pharmaceuticals, Inc. An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
CA2737447A1 (en) 2011-04-27 2012-10-27 Antony Paul Hornby Hayley's comet
US9104993B2 (en) 2011-04-28 2015-08-11 Lantronix, Inc. Asset management via virtual tunnels
GB2491118B (en) 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
EP2747770A1 (en) 2011-08-26 2014-07-02 BIAL - Portela & Cª S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US9254272B2 (en) 2011-11-30 2016-02-09 Sutter West Bay Hospitals Resorcinol derivatives
GB2504263B (en) 2012-06-08 2015-09-16 Gw Pharma Ltd Synergistic therapies for neuroprotection
DE102012105063C5 (de) 2012-06-12 2023-09-14 Thc Pharm Gmbh The Health Concept Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
AU2014206036B2 (en) 2013-01-08 2017-11-02 Universidade De Sao Paulo - Usp Fluorinated CBD compounds, compositions and uses thereof
CN103110582A (zh) 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
WO2014145490A2 (en) 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
LT2976074T (lt) 2013-03-19 2020-03-25 Universitat Pompeu-Fabra Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis
JP6300613B2 (ja) 2013-04-09 2018-03-28 キヤノン株式会社 トナー用樹脂およびトナー
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
HUE044975T2 (hu) 2013-10-29 2019-12-30 Biotech Inst Llc Speciális kannabisz termesztése, feldolgozása és alkalmazása
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
US9259449B2 (en) * 2014-01-07 2016-02-16 Joshua Michael Raderman Method for modifying THC content in a lipid-based extract of cannabis
US10052339B2 (en) 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
CN103913888B (zh) 2014-03-28 2016-08-17 京东方科技集团股份有限公司 一种彩膜基板、显示装置及彩膜基板的制造方法
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
WO2015187988A1 (en) 2014-06-04 2015-12-10 Intellimedix Composition and methods of treating epilepsy and/or epilepsy-related disorders
GB2527591A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd 7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
WO2016010827A1 (en) 2014-07-14 2016-01-21 Librede Inc. Production of cannabinoids in yeast
US9492438B2 (en) 2014-07-25 2016-11-15 Bette Pollard Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system
WO2016022936A1 (en) 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
CA2859934A1 (en) 2014-09-22 2016-03-22 A. Paul Hornby Hayley's comet ii
GB2531283A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531280A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
MX2017005277A (es) 2014-10-21 2018-01-11 United Cannabis Corp Extractos de cannabis y métodos de preparación y uso de la misma.
CN104490873A (zh) 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物
CA2968929A1 (en) 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US10172786B2 (en) 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
US10751300B2 (en) 2015-01-25 2020-08-25 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US20160338974A1 (en) 2015-03-02 2016-11-24 Afgin Pharma, Llc Topical regional neuro affective therapy with cannabinoid combination products
BR112017018944A2 (en) 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
EP3270896A4 (en) 2015-03-19 2018-09-12 One World Cannabis Ltd. Preparations of cannabis emulsions and methods thereof
US20160317468A1 (en) 2015-04-28 2016-11-03 Raman Sankar Uses of cannabidiol for treatment of infantile spasms
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
DK3302437T4 (da) 2015-05-28 2026-02-23 Fresh Cut Dev Llc Stabile cannabinoidformuleringer
WO2017203529A1 (en) 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
WO2016199148A1 (en) 2015-06-11 2016-12-15 One World Cannabis Ltd Novel cannabinoid combination therapies for multiple myeloma (mm)
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US20170008869A1 (en) 2015-07-10 2017-01-12 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2542155B (en) 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders
GB2542797A (en) 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
JP6676176B2 (ja) 2016-01-29 2020-04-08 ユニヴァーシティー オブ ミシシッピ 生物学的に活性なカンナビジオール類似体
WO2017139496A1 (en) 2016-02-09 2017-08-17 Cevolva Biotech, Inc. Microbial engineering for the production of cannabinoids and cannabinoid precursors
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
EP3462885B1 (en) 2016-05-27 2026-07-15 Fresh Cut Development, LLC Pharmaceutical formulation comprising cannabidiol and caprylic/capric triglyceride for use in the treatment of a disease or disorder
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551985B (en) 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
US20200215022A1 (en) 2016-12-20 2020-07-09 Tilray, Inc. Novel cannabinoid compositions and methods of treating pediatric epilepsy
CN108236608B (zh) 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
JP2020517727A (ja) 2017-04-27 2020-06-18 インシス・ディベロップメント・カンパニー・インコーポレイテッド 安定なカンナビノイド製剤
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
IT201700085508A1 (it) 2017-07-26 2019-01-26 Inalco S R L Metodo per la produzione di cannabinoidi da varietà di canapa industriale
US10925525B2 (en) 2017-08-18 2021-02-23 Canon U.S.A., Inc. Combined pulse oximetry and diffusing wave spectroscopy system and control method therefor
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2568471B (en) 2017-11-15 2022-04-13 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2019100172A1 (en) 2017-11-27 2019-05-31 Beleave Inc. Extraction and purification of cannabinoid compounds
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
EP3732813A1 (en) 2017-12-29 2020-11-04 Telefonaktiebolaget LM Ericsson (publ) Methods providing transmission and/or searching of encrypted data and related devices
GB2572126B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2572125B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2572737A (en) 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2019210210A1 (en) 2018-04-27 2019-10-31 Thomas Jefferson University Nanospun hemp-based materials
WO2019211795A1 (en) 2018-05-03 2019-11-07 Radient Technologies Inc. Continuous flow microwave-assisted extraction of a cannabis biomass
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
GB2579179A (en) 2018-11-21 2020-06-17 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB2580881A (en) 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2580653A (en) 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
GB2581517A (en) 2019-02-22 2020-08-26 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2581987B (en) 2019-03-06 2021-11-17 Gw Res Ltd Use of cannabidiol in combination with antibiotics
GB2584140A (en) 2019-05-23 2020-11-25 Gw Res Ltd Use of cannabidiol in the treatment of epileptic spasms
GB2584341B (en) 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
CN110215443A (zh) 2019-07-08 2019-09-10 云南绿新生物药业有限公司 一种抗衰老、改善睡眠软胶囊的制备方法
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2586026A (en) 2019-07-29 2021-02-03 Gw Res Ltd Use of cannabidol in the treatment of Dravet syndrome
CN110279617A (zh) 2019-08-05 2019-09-27 云南绿新生物药业有限公司 一种含火麻精油的洗发水及其制备方法
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB2588461A (en) 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of absence epilepsy
GB2589306A (en) 2019-10-25 2021-06-02 Gw Res Ltd Use of cannabidiol preparations in the treatment of fragile X syndrome
GB2588457B (en) 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201918846D0 (en) 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11409517B2 (en) 2020-06-08 2022-08-09 Microsoft Technology Licensing, Llc Intelligent prefetching for OS components
GB2597281A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
GB2597317A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597311A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597323A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597309A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597316A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597318A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597315A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597312A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597308A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202014250D0 (en) 2020-09-10 2020-10-28 Gw Res Ltd Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
US20220087951A1 (en) 2020-09-18 2022-03-24 GW Research Limited Use of cannabinoids in the treatment of epilepsy
GB2598922A (en) 2020-09-18 2022-03-23 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2601755A (en) 2020-12-08 2022-06-15 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
TW202237554A (zh) 2020-12-15 2022-10-01 英商吉偉研究有限公司 新穎化合物、其製備方法及其用途
US11815187B2 (en) 2022-01-26 2023-11-14 Maag Germany Gmbh 3-port valve

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2485291A (en) * 2009-07-03 2012-05-09 Gw Pharma Ltd Cannabidiol (CBD) for use in the treatment of generalised and/or partial seizures
WO2015193667A1 (en) * 2014-06-17 2015-12-23 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
WO2015193668A1 (en) * 2014-06-17 2015-12-23 Gw Pharma Limited Use of cannabidiol in the treatment of epilepsy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Epilepsia, vol. 55, No. 6, 2014, pages 783-786 *
Epilepsy & Behavior, vol. 29, 2013, pages 574-577 *
Epilepsy & Behavior, vol. 45, 2015, pages 49-52 *
http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Physician%20Reports%20of%20Epidiolex%20Treatment%20Effect%20in%20Children%20and%20Young%20Adults%20with%20Treatment-Resistant%20Epilepsy%20from%20Physician-Led%20Expanded%20Access%20Treatment%20Program.aspx [Available online 17 June 2014] *
http://www.gwpharm.com/GW%20Pharmaceuticals%20Provides%20Update%20on%20Orphan%20Program%20in%20Childhood%20Epilepsy%20for%20Epidiolex.aspx [Available online 14 November 2013] *

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11766411B2 (en) 2014-06-17 2023-09-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11154516B2 (en) 2014-06-17 2021-10-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11311498B2 (en) 2014-06-17 2022-04-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11963937B2 (en) 2014-06-17 2024-04-23 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11701330B2 (en) 2014-06-17 2023-07-18 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11793770B2 (en) 2014-06-27 2023-10-24 GW Research Limited 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
US11446258B2 (en) 2014-10-14 2022-09-20 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11633369B2 (en) 2014-10-14 2023-04-25 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US12427160B2 (en) 2014-10-14 2025-09-30 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
US11400055B2 (en) 2014-10-14 2022-08-02 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US12318356B2 (en) 2014-10-14 2025-06-03 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
US11154517B2 (en) 2014-10-14 2021-10-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US12064399B2 (en) 2015-06-17 2024-08-20 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
US11357741B2 (en) 2015-06-17 2022-06-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US12213985B2 (en) 2016-07-01 2025-02-04 Jazz Pharmaceuticals Research Uk Limited Oral cannabinoid formulations
US12064398B2 (en) 2016-07-01 2024-08-20 Jazz Pharmaceuticals Research Uk Limited Parenteral formulations
GB2551987A (en) * 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
US11229612B2 (en) 2016-07-01 2022-01-25 GW Research Limited Parenteral formulations
US11426362B2 (en) 2017-02-17 2022-08-30 GW Research Limited Oral cannabinoid formulations
US12263139B2 (en) 2017-06-23 2025-04-01 Jazz Pharmaceuticals Research Uk Limited Use of cannabidiol in the treatment of tuberous sclerosis complex
EP3684411A1 (en) * 2017-09-19 2020-07-29 Zynerba Pharmaceuticals, Inc. Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
US11419829B2 (en) 2017-09-29 2022-08-23 GW Research Limited Use of cannabidiol in combination with 5-HT2B receptor agonists or amphetamines in the treatment of epilepsy
WO2019064031A1 (en) 2017-09-29 2019-04-04 GW Research Limited USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINES IN THE TREATMENT OF EPILEPSY
GB2568809B (en) * 2017-09-29 2022-04-27 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568809A (en) * 2017-09-29 2019-05-29 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
AU2018341091B2 (en) * 2017-09-29 2024-09-26 Jazz Pharmaceuticals Research Uk Limited Use of cannabidiol in combination with 5-HT2B receptor agonists or amphetamins in the treatment of epilepsy
GB2568471B (en) * 2017-11-15 2022-04-13 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568471A (en) * 2017-11-15 2019-05-22 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
AU2018374550B2 (en) * 2017-12-01 2024-07-25 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
WO2019106386A1 (en) * 2017-12-01 2019-06-06 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US12383567B2 (en) 2017-12-01 2025-08-12 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
US11806319B2 (en) 2018-01-03 2023-11-07 GW Research Limited Pharmaceutical composition comprising a cannabinoid
EP3743053B1 (en) * 2018-01-24 2023-11-29 GW Research Limited Use of cannabinoids in the treatment of epilepsy
GB2572737A (en) * 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2579179A (en) * 2018-11-21 2020-06-17 Gw Res Ltd Cannabidiol-type cannabinoid compound
WO2021079151A1 (en) * 2019-10-25 2021-04-29 GW Research Limited Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
GB2588460A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
EP4048241A1 (en) * 2019-10-25 2022-08-31 GW Research Limited Use of cannabidiol preparations in the treatment of absence epilepsy
US20240091241A1 (en) * 2019-10-25 2024-03-21 GW Research Limited Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
GB2590187B (en) * 2019-11-21 2024-07-31 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB2590187A (en) * 2019-11-21 2021-06-23 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB2592117A (en) * 2019-12-19 2021-08-18 Gw Res Ltd Oral cannabinoid formulations
GB2592117B (en) * 2019-12-19 2022-07-06 Gw Res Ltd Oral solution cannabinoid formulations
US12102619B2 (en) 2020-02-27 2024-10-01 Jazz Pharmaceuticals Research Uk Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160795B2 (en) 2020-02-27 2021-11-02 GW Research Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11406623B2 (en) 2020-02-27 2022-08-09 GW Research Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US12661365B2 (en) 2020-06-18 2026-06-23 Jazz Pharmaceuticals Research Uk Limited Use of cannabidiol in the treatment of epilepsy
GB2597286A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes
WO2022017949A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with chrna4 mutation
GB2597287A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2599203A (en) * 2020-07-20 2022-03-30 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017957A1 (en) 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage
WO2022017913A1 (en) 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022017930A1 (en) 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with jeavon's syndrome
WO2022017931A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with ohtahara syndrome or ohtahara syndrome secondary to aimp1 mutation
WO2022017937A1 (en) 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rett syndrome
WO2022017940A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Cannabidiol for use in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022017915A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Cannabidiol for use in the treatment of seizures associated with brain damage
WO2022017956A1 (en) 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with herpes simplex virus
WO2022017927A1 (en) 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with perisylvian fissure syndrome
US12558362B2 (en) 2020-07-20 2026-02-24 Jazz Pharmaceuticals Research Uk Limited Use of cannabidiol in the treatment of seizures associated with rett syndrome
WO2022017917A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Cannabidiol for use in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017920A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Cannabidiol for use in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017944A1 (en) 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with bilateral cerebral dysgenesis
WO2022017919A1 (en) 2020-07-20 2022-01-27 GW Research Limited Cannabidiol for use in the treatment of seizures associated with hydrocephalus
GB2597302A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage
GB2597293A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597305A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597301A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with herpes simplex virus
GB2597291A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597303A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
GB2597321A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022123236A1 (en) 2020-12-08 2022-06-16 GW Research Limited Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes in patients taking brivaracetam
GB2601755A (en) * 2020-12-08 2022-06-15 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes
US12569505B2 (en) 2022-08-12 2026-03-10 Jazz Pharmaceuticals Research Uk Limited Oral solid dosage forms comprising cannabinoids

Also Published As

Publication number Publication date
NZ738403A (en) 2024-07-26
MX2022015027A (es) 2023-01-04
EP3310390A1 (en) 2018-04-25
AU2016278088A1 (en) 2018-01-18
US20200297656A1 (en) 2020-09-24
US20170007551A1 (en) 2017-01-12
GB201510664D0 (en) 2015-07-29
MX381089B (es) 2025-03-12
US12064399B2 (en) 2024-08-20
AU2016278088B2 (en) 2021-08-19
US20240350428A1 (en) 2024-10-24
US10709671B2 (en) 2020-07-14
HK1253580A1 (zh) 2019-06-21
JP2018521042A (ja) 2018-08-02
US11357741B2 (en) 2022-06-14
AU2021269374B2 (en) 2023-12-14
JP6983076B2 (ja) 2021-12-17
MX2017016212A (es) 2018-04-13
US20220387348A1 (en) 2022-12-08
WO2016203239A1 (en) 2016-12-22
EP3984531A1 (en) 2022-04-20
JP2022033807A (ja) 2022-03-02
CA2989779A1 (en) 2016-12-22
AU2021269374A1 (en) 2021-12-16
MX2021003331A (es) 2022-11-28

Similar Documents

Publication Publication Date Title
AU2021269374B2 (en) Use of cannabinoids in the treatment of epilepsy
AU2022209295B2 (en) Use of cannabidiols in the treatment of epilepsy
AU2021204353B2 (en) Use of cannabinoids in the treatment of epilepsy
CA2963202C (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
WO2017168138A1 (en) Use of cannabinoids in the treatment of sturge weber syndrome
EP3206679A1 (en) Use of cannabidiol in the treatment of epilepsy
CA2989779C (en) Use of cannabinoids in the treatment of epilepsy
HK40073373A (en) Use of cannabidiol for the treatment of focal seizures in dravet syndrome

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: GW RESEARCH LIMITED

Free format text: FORMER OWNER: GW PHARMA LIMITED

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)